{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:46:57Z","timestamp":1791362817444,"version":"4.3.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To describe mesenchymal stromal cells (MSCs) in the treatment of hematopoietic stem cell transplantation (HSCT) complications and to assess its safety and efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Single-center retrospective study (2016\u20132023). Patients under 20 years who received MSCs for the treatment of HSCT-related complications were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty patients (53.7% boys), median age at transplant 11 years (range 2\u201319) were included. MSCs indications were: graft-vs.-host disease (GVHD) in 18 patients (60%), of them 13 had acute GVHD (43.3%) and 5 chronic GVHD (16.7%); Grade 3\u20134 hemorrhagic cystitis (HC) in 4 (13.3%); poor graft function (PGF) in 6 (20%), 5 of them receiving MSCs with a CD34 stem cell-boost coinfusion; graft failure (GF) in 2 (6.7%), to enhance engraftment after a subsequent HSCT. Infusion-related-adverse-events were not reported. Overall response (OR) was 83% (25\/30); 44% of responders (11\/25) showed complete response (CR). OR for GVHD, HC, PGF and GF was 83.3%, 100%, 66.7% and 100% respectively. Response rate was 40% (95% CI: 20\u201355) and 79% (95% CI: 57\u201389) at 15 and 30 days. With a median follow-up of 21 months (IQR11\u201352.5), overall survival (OS) was 86% (95% CI: 74\u2013100) and 79% (95% CI: 65\u201395) at 6 and 12 months post-MSCs infusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In our study, the most frequent indication of MSCs was refractory aGVHD (43.3%). Response rates were high (OR 83%) and safety profile was good.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1375493","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:24:36Z","timestamp":1715232276000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Mesenchymal stromal cells in the treatment of pediatric hematopoietic cell transplantation-related complications (graft vs. host disease, hemorrhagic cystitis, graft failure and poor graft function): a single center experience"],"prefix":"10.3389","volume":"12","author":[{"given":"Maria","family":"P\u00e9rez-Torres Lobato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Benitez-Carabante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Torrents","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Castillo Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luz","family":"Uria Oficialdegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Panesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Alonso-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Oliveras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Renedo-Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Vives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Diaz-de-Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3402\/jmahp.v4.31036","article-title":"Advanced therapy medicinal products: current and future perspectives","volume":"25","author":"Hanna","year":"2016","journal-title":"J Mark Access Health Policy"},{"key":"B2","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"756029","DOI":"10.3389\/fmed.2021.756029","article-title":"Cell therapy: types, regulation, and clinical benefits","volume":"8","author":"El-Kadiry","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"20150017","DOI":"10.1098\/rstb.2015.0017","article-title":"Cell-based therapy technology classifications and translational challenges","volume":"370","author":"Mount","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12015-018-9866-1","article-title":"Biological products: cellular therapy and FDA approved products","volume":"15","author":"Golchin","year":"2019","journal-title":"Stem Cell Rev Reports"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1097\/HS9.0000000000000151","article-title":"Mesenchymal stromal cells: role in the BM niche and in the support of hematopoietic stem cell transplantation","volume":"2","author":"Crippa","year":"2018","journal-title":"Hemasphere"},{"key":"B7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/0963689719837897","article-title":"The pros and cons of mesenchymal stem cell-based therapies","volume":"28","author":"Musia\u0142-Wysocka","year":"2019","journal-title":"Cell Transplant"},{"key":"B8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12015-011-9229-7","article-title":"The origins of mesenchymal stromal cell heterogeneity","volume":"7","author":"Pevsner-Fischer","year":"2011","journal-title":"Stem Cell Rev Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.bbmt.2010.11.026","article-title":"MSCs in hematopoietic cell transplantation","volume":"17","author":"Horwitz","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B10","first-page":"248","article-title":"Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art","volume":"3","author":"Malgieri","year":"2010","journal-title":"Int J Clin Exp Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.imlet.2015.06.013","article-title":"Mesenchymal stromal cells and hematopoietic stem cell transplantation","volume":"168","author":"Bernardo","year":"2015","journal-title":"Immunol Lett"},{"key":"B12","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.beha.2004.06.003","article-title":"Mesenchymal stem cells and haematopoietic stem cell transplantation","volume":"17","author":"Bacigalupo","year":"2004","journal-title":"Best Pract Res Clin Haematol"},{"key":"B14","article-title":"Hematopoietic stem cell transplantation","volume-title":"StatPearls","author":"Khaddour","year":"2023"},{"key":"B15","doi-asserted-by":"publisher","first-page":"CD009768","DOI":"10.1002\/14651858.CD009768.pub2","article-title":"Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition","volume":"1","author":"Fisher","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"761616","DOI":"10.3389\/fimmu.2021.761616","article-title":"Mesenchymal stromal cells for the treatment of graft versus host disease","volume":"12","author":"Kelly","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"567210","DOI":"10.3389\/fimmu.2020.567210","article-title":"Mesenchymal stromal cells in pediatric hematopoietic cell transplantation a review and a pilot study in children treated with decidua stromal cells for acute graft-versus-host disease","volume":"11","author":"Ringd\u00e9n","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13287-021-02304-x","article-title":"Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"12","author":"Li","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13287-015-0155-5","article-title":"Mesenchymal stromal cells enhance the engraftment of hematopoietic stem cells in an autologous mouse transplantation model","volume":"6","author":"Fern\u00e1ndez-Garc\u00eda","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1106464","DOI":"10.3389\/fimmu.2023.1106464","article-title":"Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: a multicenter prospective analysis","volume":"14","author":"Servais","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1089\/scd.2009.1809.edi","article-title":"Mesenchymal stromal cells as first-line treatment of graft failure after hematopoietic stem cell transplantation","volume":"18","author":"Ringd\u00e9n","year":"2009","journal-title":"Stem Cells Dev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e13618","DOI":"10.1111\/petr.13618","article-title":"Effects and long-term follow-up of using umbilical cord blood-derived mesenchymal stromal cells in pediatric patients with severe BK virus-associated late-onset hemorrhagic cystitis after unrelated cord blood transplantation","volume":"24","author":"Tong","year":"2020","journal-title":"Pediatr Transplant"},{"key":"B23","doi-asserted-by":"publisher","first-page":"959658","DOI":"10.3389\/fimmu.2022.959658","article-title":"Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease","volume":"13","author":"Stenger","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American society for transplantation and cellular therapy","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.bbmt.2014.05.016","article-title":"CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation","volume":"20","author":"Stasia","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/j.1537-2995.2011.03400.x","article-title":"Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation","volume":"52","author":"S\u00e1nchez-Guijo","year":"2012","journal-title":"Transfusion"},{"key":"B27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00277-018-3523-2","article-title":"Donor-derived marrow mesenchymal stromal cell co-transplantation following a haploidentical hematopoietic stem cell transplantation trail to treat severe aplastic anemia in children","volume":"98","author":"Wang","year":"2019","journal-title":"Ann Hematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.bbmt.2014.06.015","article-title":"Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease","volume":"20","author":"S\u00e1nchez-Guijo","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jcyt.2015.10.001","article-title":"Evaluation of a cell-banking strategy for the production of clinical grade mesenchymal stromal cells from Wharton\u2019s jelly","volume":"18","author":"Oliver-Vila","year":"2016","journal-title":"Cytotherapy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s12026-023-09385-1","article-title":"Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use","volume":"71","author":"Torrents","year":"2023","journal-title":"Immunol Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10616-021-00474-3","article-title":"Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use","volume":"73","author":"Garc\u00eda-Mu\u00f1oz","year":"2021","journal-title":"Cytotechnology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.jcyt.2016.05.012","article-title":"Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow-derived multipotent mesenchymal stromal cells","volume":"18","author":"Codinach","year":"2016","journal-title":"Cytotherapy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount Sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3324\/haematol.2011.055186","article-title":"Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a chronic graft-versus-host disease consortium study","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.1995.13.5.1103","article-title":"Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation","volume":"13","author":"Bedi","year":"1995","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02251-0","article-title":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","author":"Sureda","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.transproceed.2019.01.023","article-title":"Mesenchymal stem cells as a salvage treatment for severe refractory graft-vs-host disease in children after bone marrow transplantation","volume":"51","author":"Krasowska-Kwiecien","year":"2019","journal-title":"Transplant Proc"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/cells8121577","article-title":"Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation \u201cMSC-FFM\"-outcome report of 92 patients","volume":"8","author":"Bonig","year":"2019","journal-title":"Cells"},{"key":"B41","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41409-018-0102-z","article-title":"Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)","volume":"53","author":"Bader","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.bbmt.2008.03.012","article-title":"Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease","volume":"15","author":"Kebriaei","year":"2009","journal-title":"Biol Blood Marrow Transplan"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.bbmt.2010.03.017","article-title":"Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population","volume":"16","author":"Lucchini","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bjh.12545","article-title":"Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease","volume":"163","author":"Ball","year":"2013","journal-title":"Br J Haematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.bbmt.2020.01.026","article-title":"Study 275: updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B47","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","article-title":"A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.bbmt.2016.06.020","article-title":"Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study","volume":"22","author":"Grube","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/bmt.2010.275","article-title":"Mesenchymal stromal cells as treatment for chronic GVHD","volume":"46","author":"Ringden","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"B50","doi-asserted-by":"crossref","first-page":"1732e40","DOI":"10.1038\/bmt.2010.195","article-title":"Mesenchymal stem cell as salvage treatment for refractory chronic GVHD","volume":"45","author":"Weng","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B51","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bbmt.2013.11.033","article-title":"Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients","volume":"20","author":"Introna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/bmt.2010.262","article-title":"Pooled MSCs for treatment of severe hemorrhage","volume":"46","author":"Ringd\u00e9n","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"B53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.beha.2011.01.003","article-title":"Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages","volume":"24","author":"Ringden","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jcyt.2015.11.010","article-title":"Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"18","author":"Kallekleiv","year":"2016","journal-title":"Cytotherapy"},{"key":"B55","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/sj.leu.2405090","article-title":"The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study","volume":"22","author":"Ning","year":"2008","journal-title":"Leukemia"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1186\/s13287-021-02304-x","article-title":"Effect of human umbilical cord mesenchymal stem cells on immune reconstruction of acute lymphoblastic leukemia children undergoing allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Xiang","year":"2017","journal-title":"Chin J Tissue Eng Res"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1375493\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:24:40Z","timestamp":1715232280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1375493\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":56,"alternative-id":["10.3389\/fped.2024.1375493"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1375493","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"article-number":"1375493"}}